FY2026 EPS Estimates for Edesa Biotech Cut by Zacks Research

Edesa Biotech, Inc. (NASDAQ:EDSA) – Zacks Research reduced their FY2026 earnings per share estimates for Edesa Biotech in a note issued to investors on Monday, March 2nd. Zacks Research analyst D. Bautz now expects that the company will earn ($0.97) per share for the year, down from their previous estimate of ($0.94). The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.75) per share.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Edesa Biotech in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.00.

Edesa Biotech Price Performance

EDSA stock opened at $4.35 on Wednesday. Edesa Biotech has a fifty-two week low of $0.72 and a fifty-two week high of $4.35. The stock has a market capitalization of $36.32 million, a price-to-earnings ratio of -3.78 and a beta of 0.05. The business’s fifty day moving average price is $1.40 and its two-hundred day moving average price is $1.88.

Edesa Biotech (NASDAQ:EDSA) last released its quarterly earnings results on Friday, February 13th. The company reported ($0.28) earnings per share for the quarter, hitting the consensus estimate of ($0.28). The firm had revenue of $0.10 million for the quarter.

Insider Buying and Selling at Edesa Biotech

In related news, CEO Pardeep Nijhawan bought 30,000 shares of Edesa Biotech stock in a transaction dated Friday, February 27th. The shares were bought at an average cost of $2.22 per share, with a total value of $66,600.00. Following the acquisition, the chief executive officer owned 371,702 shares in the company, valued at $825,178.44. This trade represents a 8.78% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 22.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. DRW Securities LLC acquired a new stake in Edesa Biotech during the fourth quarter worth about $191,000. Diadema Partners LP acquired a new position in shares of Edesa Biotech in the 4th quarter valued at approximately $77,000. State Street Corp bought a new stake in shares of Edesa Biotech during the 4th quarter worth approximately $27,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Edesa Biotech during the 3rd quarter worth approximately $36,000. Institutional investors and hedge funds own 5.50% of the company’s stock.

About Edesa Biotech

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.